Premium
Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival
Author(s) -
Seales Eric C.,
Micoli Keith J.,
McDonald Jay M.
Publication year - 2005
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20659
Subject(s) - osteoclast , microbiology and biotechnology , nfat , rankl , calmodulin , bone resorption , transcription factor , chemistry , cancer research , biology , medicine , endocrinology , receptor , calcium , activator (genetics) , biochemistry , gene
Increased osteoclastic resorption and subsequent bone loss are common features of many debilitating diseases including osteoporosis, bone metastases, Paget's disease, and rheumatoid arthritis. While rapid progress has been made in elucidating the signaling pathways directing osteoclast differentiation and function, a comprehensive picture is far from complete. Here, we explore the role of the Ca 2+ ‐activated regulator calmodulin in osteoclastic differentiation, functional bone resorption, and apoptosis. During active bone resorption, calmodulin expression is increased, and calmodulin concentrates at the ruffled border, the organelle utilized for acid transport and bone dissolution. Pharmacologic inhibitors of calmodulin, several of which are already used clinically as anti‐cancer and anti‐psychotic agents, inhibit osteoclastic acid transport, suggesting their potential as bone‐sparing drugs. Recent studies also implicate calmodulin in osteoclast apoptosis through a mechanism involving its direct interaction with the death receptor Fas. During osteoclastogenesis, RANKL‐induction stimulates a rise in intracellular Ca 2+ , which in turn activates calmodulin and its downstream effectors. In particular, the Ca 2+ /calmodulin‐dependent phosphatase calcineurin and its targets, the NFAT family of transcription factors, have been posited as the master regulators of osteoclastogenesis. However, recent in vivo and in vitro studies demonstrate that another Ca 2+ /calmodulin‐regulated effector protein, CaMKII, is also involved. CaMKII +/− mutant mice have reduced osteoclast numbers, and CaMKII antagonists inhibit osteoclastogenesis in vitro. Furthermore, CaMKII is known to activate AP‐1 transcription factors, which are also required for RANKL‐induced osteoclast gene transcription, and recent findings suggest that CaMKII can down‐regulate gp130, a cytokine receptor involved in bone remodeling and implicated in numerous osteo‐articular diseases. J. Cell. Biochem. © 2005 Wiley‐Liss, Inc.